Satellos Bioscience (NASDAQ:MSLE) Now Covered by Cantor Fitzgerald

Analysts at Cantor Fitzgerald began coverage on shares of Satellos Bioscience (NASDAQ:MSLE) in a note issued to investors on Wednesday,Benzinga reports. The brokerage set an “overweight” rating on the stock.

MSLE has been the topic of a number of other research reports. Weiss Ratings initiated coverage on shares of Satellos Bioscience in a report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Satellos Bioscience Stock Down 18.1%

MSLE stock opened at $9.54 on Wednesday. Satellos Bioscience has a one year low of $4.53 and a one year high of $13.39. The stock has a market cap of $147.49 million, a price-to-earnings ratio of -7.95 and a beta of 1.10.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.